| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Leukemia Service, Departments of Medicine and Biostatistics, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, New York 10021 [J. G. J., T. D., T-J. Y., D. A. S.], and Protein Design Labs, Inc., Fremont, California 94555 [L.D.]
Despite achieving complete remission with retinoic acid (RA), most patients with acute promyelocytic leukemia (APL) have minimal residual disease detectable by reverse transcription-PCR (RT-PCR) amplification. HuM195, a humanized monoclonal antibody reactive with the cell surface antigen CD33, specifically targets and kills myeloid leukemia cells. We studied whether HuM195 could eliminate minimal residual disease in patients with APL by using RT-PCR. After attaining clinical complete remission with RA and/or chemotherapy, patients received HuM195 twice weekly for 3 weeks. Patients in first remission were given consolidation chemotherapy, generally with three cycles of idarubicin and cytarabine. Patients in second or greater remission did not receive chemotherapy. All patients received six monthly courses of maintenance with two doses of HuM195. Twenty-five of 27 patients treated in first remission had positive RT-PCR determinations before HuM195 treatment. Of the 22 patients evaluable for conversion of positive RT-PCR assays, 11 (50%) became RT-PCR negative after HuM195 treatment without additional therapy. Within the subset of patients who received RA alone as induction, 8 of 18 evaluable patients (44%) had negative RT-PCR determinations after HuM195 treatment but before chemotherapy. Among similar patients treated on earlier studies, 7 of 34 patients (21%) induced into remission with RA and then maintained on the drug for 1 month were RT-PCR negative before chemotherapy (P = 0.07). Twenty-five of 27 patients with newly diagnosed APL (93%) remain in clinical complete remission for 7+ to 58+ months, with median follow-up of 29 months. Seven patients in second or third remission and one patient in molecular relapse were also treated. Only one of these patients became RT-PCR negative after treatment with HuM195. These data suggest that HuM195 has activity against minimal residual disease in APL, particularly in newly diagnosed patients.
This article has been cited by other articles:
|
|
 |
|
  Z.-Y. Wang and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood, March 1, 2008; 111(5): 2505 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pagel, N. Hedin, L. Drouet, B. L. Wood, A. Pantelias, Y. Lin, D. K. Hamlin, D. S. Wilbur, A. K. Gopal, D. Green, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy Blood, February 15, 2008; 111(4): 2261 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Burnett and S. Knapper Targeting Treatment in AML Hematology, January 1, 2007; 2007(1): 429 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Estey, G. Garcia-Manero, A. Ferrajoli, S. Faderl, S. Verstovsek, D. Jones, and H. Kantarjian Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia Blood, May 1, 2006; 107(9): 3469 - 3473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lin, J. M. Pagel, D. Axworthy, A. Pantelias, N. Hedin, and O. W. Press A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Protein for Pretargeted Radioimmunotherapy of Hematologic Malignancies. Cancer Res., April 1, 2006; 66(7): 3884 - 3892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Jabbour, E. Estey, and H. M. Kantarjian Adult Acute Myeloid Leukemia Mayo Clin. Proc., February 1, 2006; 81(2): 247 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lo-Coco and E. Ammatuna The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment Hematology, January 1, 2006; 2006(1): 156 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Feldman, J. Brandwein, R. Stone, M. Kalaycio, J. Moore, J. O'Connor, N. Wedel, G. J. Roboz, C. Miller, R. Chopra, et al. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4110 - 4116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Christiansen and A. K. Rajasekaran Biological impediments to monoclonal antibody-based cancer immunotherapy Mol. Cancer Ther., November 1, 2004; 3(11): 1493 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lo-Coco, G. Cimino, M. Breccia, N. I. Noguera, D. Diverio, E. Finolezzi, E. M. Pogliani, E. Di Bona, C. Micalizzi, M. Kropp, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia Blood, October 1, 2004; 104(7): 1995 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello Immunotherapeutic Approaches for Hematologic Malignancies Hematology, January 1, 2004; 2004(1): 337 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Stone The Difficult Problem of Acute Myeloid Leukemia in the Older Adult CA Cancer J Clin, November 1, 2002; 52(6): 363 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. McDevitt, R. D. Finn, C. R. Divgi, A. M. Ballangrud, K. A. Hamacher, D. Ma, J. L. Humm, et al. Targeted alpha particle immunotherapy for myeloid leukemia Blood, July 30, 2002; 100(4): 1233 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Estey, F. J. Giles, M. Beran, S. O'Brien, S. A. Pierce, S. H. Faderl, J. E. Cortes, and H. M. Kantarjian Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia Blood, May 13, 2002; 99(11): 4222 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Countouriotis, T. B. Moore, and K. M. Sakamoto Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies Stem Cells, May 1, 2002; 20(3): 215 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-K. V. Cheung and S. Modak Oral (1->3),(1->4)-{beta}-D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma Clin. Cancer Res., May 1, 2002; 8(5): 1217 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe Acute promyelocytic leukemia: evolving therapeutic strategies Blood, February 1, 2002; 99(3): 759 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Jurcic, S. D. Nimer, D. A. Scheinberg, T. DeBlasio, R. P. Warrell Jr, and W. H. Miller Jr Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia Blood, November 1, 2001; 98(9): 2651 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kee Shin, E. Young Choi, S. Hyung Kim, J. Chung, D. Hyun Chung, W. Seo Park, K. Cheon Jung, H. Sik Kim, S. Park, H. Jin Kim, et al. Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus Am. J. Pathol., April 1, 2001; 158(4): 1473 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick Acute Myeloid Leukemia Hematology, January 1, 2001; 2001(1): 62 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Gorin, E. Estey, R. J. Jones, H. I. Levitsky, I. Borrello, and S. Slavin New Developments in the Therapy of Acute Myelocytic Leukemia Hematology, January 1, 2000; 2000(1): 69 - 89. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
